The Hemostasis and Thrombosis Center Of Cremona carried out research on the importance of measuring anticoagulant drugs administered orally in patients with atrial fibrillation.
Study of the Hemostasis and Thrombosis Center
The study involved well 1,657 people followed by 27 centres, affiliated with the Federation for the Diagnosis of Thrombosis and the Surveillance of Antithrombotic Therapies (FCSA). The patients in question started the anticoagulant treatment to prevent brain strokeshowing how low plasma levels affect the development of thrombotic complications.
The study was conducted by the Arianna Anticoagulation Foundation and coordinated by Sophie Testa, director of Analysis laboratory and Haemostasis and Thrombosis Center of Cremonaand by 20 other members who are specialists in the subject, including Claudia Dellanoce, Oriana Paoletti, Rossella Morandini and Maurizio Tala.
The study took place last March in Bologna, during the conference promoted by the Arianna Foundation on anticoagulation. Today it is published by the magazine Blood Advances.
Sophie Testa and Gualtiero Palareti
“Although the low number of thrombotic events confirms the efficacy and safety of these drugs, the possibility of identifying patients who may not respond adequately to treatment through a measurement of drug activity performed at the beginning of therapy is today an extremely important diagnostic tool clinic in order to reduce the risk of thrombotic complications,” he explains Sophie Testa.
Photo 1 of 3
Hemostasis Center Team
Photo 2 of 3
Analysis Laboratory Team
Photo 3 of 3
Sophie Testa, Director of the Haemostasis and Thrombosis Laboratory in Cremona
“Measuring drug levels at the start of therapy could improve the safety of treatment, particularly in moles patients at high cardiovascular risk or with other risk conditions. However, further studies are needed to establish whether modifying therapy based on measured plasma levels can lead to an effective reduction in vascular events,” he added. Gualtiero Palareti, President of the Arianna Anticoagulation Foundation.
